Ironwood Pharmaceuticals, Inc.
IRWD
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $701.3M
$4.26
▼ -0.70%
P/E
5.48
Mkt Cap
$701.3M
52-Wk Range
$1.05–$5.78
52-Week Range
$1.05 - $5.78
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 277.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Established market presence with FDA-approved LINZESS generating consistent revenue streams
- Strategic partnerships with major pharmaceutical companies (AbbVie, AstraZeneca, Astellas) providing development and commercialization support
- Proprietary GC-C agonist platform technology with multiple pipeline candidates addressing unmet medical needs
- Diversified pipeline extending beyond GI into visceral pain and immunology, reducing dependency on single product
Bear Case
1 risk
- Low volatility (beta 0.2).
Growth
Moderate growth ahead
Strong operating leverage (33% operating margin)
Value
Deep value opportunity - significant discount to Large Cap Pharma peers
Momentum
Hot
+29.5% over 3m
Quality
Excellent
Exceptional business - top-tier fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying IRWD right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 9, 2026
AUG 6, 2026
Reported EPS of $0.31 vs $0.32 consensus (-3.1% surprise). Revenue of $113.0M vs $114.8M expected (-1.6%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-3.1%
Revenue trend · last 8Q
—
-23%
-45%
-10%
+33%
-47%
+159%
+33%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$91.6M
$90.5M
$41.1M
$85.2M
$122.1M
$47.7M
$106.5M
$113.0M
Margins · last 8Q
Gross
100.0%
Operating
70.2%
Profit
45.4%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How IRWD stacks vs Drug Manufacturers - Specialty & Generic
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related